701 Lee Road
Suite 103
Wayne, PA 19087
United States
484 324 7933
https://www.aclaristx.com
Settore/i:
Settore:
Impiegati a tempo pieno: 86
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Neal S. Walker D.O., M.D. | Co-Founder, President, Chairman & Interim CEO | 955,69k | N/D | 1970 |
Dr. Joseph Monahan Ph.D. | Chief Scientific Officer | 600,02k | N/D | 1957 |
Mr. Kevin Balthaser | Chief Financial Officer | N/D | N/D | 1988 |
Mr. Matthew Rothman J.D. | General Counsel & Corporate Secretary | N/D | N/D | N/D |
Dr. Jon Jacobsen Ph.D. | Senior Vice President of Chemistry | N/D | N/D | N/D |
Mr. James Loerop | Chief Business Officer | N/D | N/D | 1965 |
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
L'ISS Governance QualityScore di Aclaris Therapeutics, Inc. al 1 marzo 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 8.